PharmaDiagnostics, a developer of label-free screening technology that does not require specialised instrumentation, has appointed Dr Sylviane Boucharens as director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.
Boucharens will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and in developing business globally. She worked at Merck from 2000 to 2011. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).
PharmaDiagnostics appoints director of assay development
Former pharma department head joins Belgian firm
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA